Plaque Psoriasis

The FDA has accepted a New Drug Application for tapinarof cream for the treatment of plaque psoriasis in adults, Dermavant Sciences announced in a press release.

A new drug application has been submitted to the FDA for tapinarof cream for the treatment of plaque psoriasis in adults, Dermavant Sciences announced in a press release.

Switching to bimekizumab resulted in better outcomes among certain patients with psoriasis who did not respond as well to adalimumab, according to results presented at AAD VMX 2021.

In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, discussed results from a recent study evaluating bimekizumab in patients with psoriasis.

In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, spoke with Healio about research on deucravacitinib presented at AAD VMX 2021.

In this video, April Armstrong, MD, MPH, of the Keck School of Medicine at the University of Southern California, Los Angeles, spoke with Healio about the results and clinical implications of the POETYK PSO-1 and POETYK PSO-2 trials.

Tapinarof cream 1% met its secondary endpoints in two phase 3 trials for the treatment of plaque psoriasis, according to a poster presented at AAD VMX 2021.

Deucravacitinib showed significant improvement in plaque psoriasis compared with both placebo and apremilast, according to two studies presented at AAD VMX 2021.

In this video from AAD VMX 2021, Stephen Rozzo, PhD, senior director of dermatology medical affairs at Sun Pharmaceuticals, discusses meeting presentations showing lasting efficacy of tildrakizumab for the treatment of plaque psoriasis.

A phase 3 study found bimekizumab to be more efficacious in the treatment of plaque psoriasis than both ustekinumab and placebo.